- The disease
- Castration-resistant prostate cancer (CRPC) is a form of prostate cancer that continues to grow even when testosterone levels are reduced to very low levels by hormonal treatment. It is generally considered an advanced stage of the disease and carries a poorer outlook than hormone-sensitive prostate cancer. Many patients with CRPC have cancer that has spread to the bones or other organs (per ClinicalTrials.gov NCT07259213). Management at this stage typically involves additional systemic treatments, including hormone therapies, chemotherapy, and, more recently, radioligand therapies.
- What the asset is trying to do
- RAD 204 is described in its clinical registry entry as 177Lu-anti-PD-L1 sdAb, meaning it combines lutetium-177 (a radioactive isotope) with a single-domain antibody (sdAb, sometimes called a nanobody) that targets PD-L1, a protein expressed on some cancer cells and immune cells (per ClinicalTrials.gov NCT06305962). The lutetium-177 payload delivers localised radiation directly to cells carrying PD-L1 on their surface. This approach differs from conventional PD-L1 checkpoint inhibitors, which work by blocking the PD-L1 immune checkpoint signal rather than delivering radiation. The asset is classified by Radiopharm Theranostics under the radioligand category, which combines targeted delivery with radiation (theranostics).
- What the trial is measuring, and why it matters
- The lead trial (NCT06305962) is an Early Phase 1 study enrolling participants with metastatic solid tumours across multiple cancer types, including non-small cell lung cancer, small cell lung cancer, triple-negative breast cancer, melanoma, head and neck squamous cell carcinoma, endometrial cancer, and mismatch-repair-deficient or MSI-high tumours (per ClinicalTrials.gov NCT06305962). Early Phase 1 studies in oncology typically focus on safety, tolerability, and dose finding as primary objectives, with preliminary signals of anti-tumour activity as exploratory endpoints. Establishing a safe and tolerable dose is the prerequisite step before larger efficacy trials can be designed.
- Efficacy benchmarks in this setting
- For context, the approved radioligand therapy lutetium-177 PSMA-617 (Pluvicto) demonstrated a radiographic progression-free survival of 8.7 months versus 3.4 months with best supportive care, and an overall survival of 15.3 months versus 11.3 months, in patients with PSMA-positive metastatic CRPC in the VISION trial (per Sartor et al, New England Journal of Medicine, 2021, NCT03511664). In the PD-L1 checkpoint inhibitor space, pembrolizumab (Keytruda) showed objective response rates of approximately 19% in MSI-high or mismatch-repair-deficient solid tumours across multiple cancer types in the KEYNOTE-158 trial (per Marabelle et al, Journal of Clinical Oncology, 2020). RAD 204 is in Early Phase 1 and its trial is not designed or powered to generate efficacy figures that are statistically comparable to these approved-therapy benchmarks.
- Commercial context
- Lutetium-177 PSMA-617 (Pluvicto, Novartis) is approved by the US FDA for PSMA-positive metastatic CRPC following prior androgen receptor pathway inhibition and taxane-based chemotherapy (per FDA approval March 2022). Several PD-L1-targeting checkpoint inhibitors are approved across various solid tumour indications, though approvals in each specific tumour type covered by the RAD 204 trial vary. RAD 204 (177Lu-RAD204) is one of multiple pipeline assets in Radiopharm Theranostics' portfolio; the company's recent announcements have highlighted RAD 101 and RAD 202 activity more prominently than RAD 204 (per ASX announcements April 2026).